1. Imatinib for refractory chronic graft-versus-host disease with fibrotic features
by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele Cimminiello, Roberto Raimondi, Guido Gini, Nicola Mordini, Adriana Balduzzi, Pietro Leoni, Armando Gabrielli, and Andrea Bacigalupo
Blood
Volume 114(3):
July 16, 2009
©2009 by American Society of Hematology

2. Overall survival probability (OS) of the 19 patients with cGVHD receiving imatinib.
Overall survival probability (OS) of the 19 patients with cGVHD receiving imatinib. OS was measured from start of imatinib treatment.
Attilio Olivieri et al. Blood 2009;114:
©2009 by American Society of Hematology

3. Cumulative incidence (CI) of treatment failure in the 19 patients with cGVHD receiving imatinib.
Cumulative incidence (CI) of treatment failure in the 19 patients with cGVHD receiving imatinib. CI was calculated from the start of imatinib to whichever event was considered as treatment failure (intolerance or lack of response).
Attilio Olivieri et al. Blood 2009;114:
©2009 by American Society of Hematology